Overview
Status
Suspended
Registry date
2022-07-21
Share capital
100.00 PLN
Registered address
Wrocław, Poland
Email
Financials
This entity has not filed any financial documents with the Financial Document Repository (RDF).
Authorized Representatives
Grzegorz Edward Kobyłecki – President of the Management Board
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Beneficial owners
No beneficial owners recorded for the company Rebio.
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Nov 13, 2025 | Dissolution without liquidation opened |
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Read-GeneS.A. | $2,163,474.84 | read-gene.com | ||
| Vitrotest Europesp. z o.o. | $233,350.77 | vitrotest.pl | ||
| VASA Therapeuticssp. z o.o. | $216,535.01 | vasatherapeutics.com | ||
| MultiqureS.A. | $149,394.35 | purebiologics.com | ||
| AI Corelabsp. z o.o. | $128,365.55 | aicorelab.com | ||
| Pominnosp. z o.o. | $65,991.17 | pominno.pl | ||
| GenomtecS.A. | $54,746.36 | genomtec.com | ||
| 4cell TherapiesS.A. | $9,123.06 | 4celltherapies.com | ||
| Centrum Transferu Technologii Meditransfer Iitdsp. z o.o. | $228.56 | iitd.pan.wroc.pl | ||
| Olenasp. z o.o. | – | imsolutions.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-12-11 | Address change (Pl. Solny 15, 50-062, Wrocław → Wrocław) | |
| 2024-12-19 | Business suspended | |
| 2022-07-21 | Entered in the register |
FAQ
The main business activity of Rebio focuses on research and experimental development on biotechnology.
The company was registered in the Polish National Court Register (KRS) on July 21, 2022.
The headquarters is located at: Wrocław.
The management board consists of: Grzegorz Edward Kobyłecki (President of the Management Board).
The share capital of the company is PLN 100 (approx. $27).
Last updated: 2026-04-02